Clinical Trials
12 trialsNCT05661955 2026-05-11
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT05238883 2025-11-21
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
NCT05789069 2025-11-21
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
NCT05542342 2025-05-14
SITISVEAL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT03493451 2024-10-26
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
Phase 2 Completed
NCT04924413 2024-07-03
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
Henan Cancer Hospital
Phase 2 Terminated
NCT05798533 2023-07-10
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Phase 1 Unknown
NCT05406466 2022-11-10
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
Fudan University
Phase 2 Unknown
NCT05104801 2021-11-04
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown